Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Artificial intelligence for diagnostic applications in rare hematologic malignancies: A systematic review

Filip Sadurski, Mousa Thalji, Rohit Sharma Nov 03, 2025 pp. 7873-7873 10.1182/blood-2025-7873

Abstract Rare hematologic malignancies (collectively accounting for ~20% of cancers) pose diagnostic challenges due to heterogeneous present...

Transcriptomic identification of functionally potent human hematopoietic stem and progenitor cells

James Ropa, Kevin Shoulars, Jimin Park et al. Nov 03, 2025 pp. 3159-3159 10.1182/blood-2025-3159

Abstract Background: Allogeneic hematopoietic cell transplantation is a potentially curative treatment for malignant and non-malignant hemato...

Assessment of minimal residual disease with droplet digital polymerase chain reaction for BRAF V600E mutation in patients with hairy cell leukemia treated with purine analogs

Gianmarco Favrin, Chiara Varraso, Silvia Zibellini et al. Nov 03, 2025 pp. 1832-1832 10.1182/blood-2025-1832

Abstract Background. BRAF (V600E) mutation is the molecular hallmark of hairy cell leukemia (HCL), being detected in more than 95% of patien...

Activation effects of chidamide on BET signaling pathways and the mechanism of  synergistic effect with BET inhibitors in Mantle Cell Lymphoma

Li Fu, Jing Shen Nov 03, 2025 pp. 7053-7053 10.1182/blood-2025-7053

Abstract Mantle cell lymphoma (MCL) is a rare, aggressive, and heterogeneous subtype of B-cell non-Hodgkin lymphoma. Emerging evidence sugge...

Targeting CCL3+mono like LSC overcomes chemotherapy resistance in NPM1 mutant AML

Zhao Yin, Xi Jia, Sijian Yu et al. Nov 03, 2025 pp. 3511-3511 10.1182/blood-2025-3511

Abstract Background: Nucleophosmin 1 mutation (NPM1mut) represents one of the most frequent genetic alterations in acute myeloid leukmia (AML...

PNH-driven hepatic vein thrombosis: A case of budd-chiari syndrome in disguise“

Sai Prasad, Shaily Agrawal, Advaitha Reddy et al. Nov 03, 2025 pp. 6740-6740 10.1182/blood-2025-6740

Abstract Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare clonal hematopoietic stem cell disorder characterised by complement-mediated in...

NOTCH pathway activation is mediated by DTX1 loss of function mutations in DLBCL

Abigail Dropik, Melissa Hopper, Janek Walker et al. Nov 03, 2025 pp. 1771-1771 10.1182/blood-2025-1771

Abstract Diffuse Large B Cell Lymphoma (DLBCL), the most common subtype of aggressive B-cell Non-Hodgkin Lymphoma (NHL), accounts for 30-40%...

Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy

Bingqi Xu, Xiaolei Pei, Dandan Yu et al. Nov 03, 2025 pp. 279-279 10.1182/blood-2025-279

Abstract Background Gene therapy using adeno-associated virus (AAV) as a vector has been successfully applied in treatin...

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Lauren Pomerantz, Sameer Parikh, Kari Rabe et al. Nov 03, 2025 pp. 3905-3905 10.1182/blood-2025-3905

Abstract Background: The synergistic mechanisms of BCL-2 inhibitors and CD20-directed antibodies in the treatment of chronic lymphocytic leuk...

Subgroup analysis in pediatric patients from the Phase 3 study of tabelecleucel for allogeneic or solid organ transplant recipients with Epstein–Barr virus-driven post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE)

Sonali Chaudhury, Ran Reshef, Sarah Nikiforow et al. Nov 03, 2025 pp. 5488-5488 10.1182/blood-2025-5488

Abstract Background: Epstein–Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) is an ultra-rare complication wit...

Tallforest: Multi-omic classifier for T-lineage acute lymphoblastic leukemia

Petri Pölönen, Yiping Fan, Shaohua Lei et al. Nov 03, 2025 pp. 336-336 10.1182/blood-2025-336

Abstract We previously demonstrated that T-lineage acute lymphoblastic leukemia (T-ALL) can be classified into 15 molecular subtypes based o...

Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study

Matthew S Davids, Alen Ostojic, Susana Wargo et al. Nov 03, 2025 pp. 3912-3912 10.1182/blood-2025-3912

Abstract Background and Significance: For patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed-duration t...

Macrophages mediate hematopoietic stem cell trans-endocytosis to coordinate regenerative stress and aging

Zixuan Xu, Yirong Zhang, Lei Li et al. Nov 03, 2025 pp. 432-432 10.1182/blood-2025-432

Abstract The hematopoietic stem cell (HSC) niche is a specialized microenvironment in the bone marrow (BM) that controls HSC activity to ens...

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Anaïs Schavgoulidze, Jérôme Lambert, Arthur Bobin et al. Nov 03, 2025 pp. 497-497 10.1182/blood-2025-497

Abstract Introduction. A recent international genomic consensus staging has standardized the high-risk (HR) definition on the basis of an NG...

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study  FIL_RI-CHOP

Alice Di Rocco, Annalisa Chiappella, Andrea Evangelista et al. Nov 03, 2025 pp. 55-55 10.1182/blood-2025-55

Abstract Background: Patients with activated (ABC) subtype diffuse large B-cell lymphoma (DLBCL) exhibit inferior outcomes following R-CHOP...

Murine modeling of cluster 1 diffuse large B-cell lymphoma reveals transformation from marginal zone lymphoma

Tianfang Ma, Elisa Mandato, Filip Garbicz et al. Nov 03, 2025 pp. 1478-1478 10.1182/blood-2025-1478

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous disease. Our comprehensive genomi...

The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut

Alix Schwarz, Simon Holzinger, Peter Herhaus et al. Nov 03, 2025 pp. 4236-4236 10.1182/blood-2025-4236

Abstract Acute graft-versus-host disease (aGvHD) remains a serious complication of allogeneic stem cell transplantation (alloSCT), most comm...

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Elise Chong, Rachel Lundberg, Matthew Lunning et al. Nov 03, 2025 pp. 1952-1952 10.1182/blood-2025-1952

Abstract Background: CD19-directed CAR T-cell therapy (CAR-T) has improved outcomes and altered the treatment landscape for patients with re...

Clonal architecture inferred from routine NGS data predicts outcome and response to JAK-inhibitors in myelofibrosis

Valentina Boldrini, Alessio Enderti, Fiorenza Irushani Vanderwert et al. Nov 03, 2025 pp. 3753-3753 10.1182/blood-2025-3753

Abstract Background: Intra-tumor heterogeneity (ITH) and mutated variant allele frequency (VAF) were associated with poor outcomes in cancers...

Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries

Leticia Marani, Maria Isabel Ayrosa Madeira, Amanda Costa et al. Nov 03, 2025 pp. 1739-1739 10.1182/blood-2025-1739

Abstract Measurable Residual Disease (MRD) monitoring by Multiparametric Flow Cytometry (MPFC) is a powerful prognostic tool in Acute Myeloi...

Palliative care for AML patients on venetoclax-based therapy: A single-center real-world study

Cheryl H. Chang, Allison O. Taylor, Nia M. Mitchell et al. Nov 03, 2025 pp. 2830-2830 10.1182/blood-2025-2830

Abstract Background: Randomized trials demonstrate that patients with AML hospitalized for intensive chemotherapy benefit significantly from...

Navigating the complement cascade: A multicenter journey from pegcetacoplan to iptacopan in paroxysmal nocturnal hemoglobinuria

Praveena Thiagarajan, Mark Orland, Serhan Unlu et al. Nov 03, 2025 pp. 1433-1433 10.1182/blood-2025-1433

Abstract Introduction: The therapeutic landscape for paroxysmal nocturnal hemoglobinuria (PNH) has rapidly evolved with multiple proximal co...

Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL

Stephen Oh, Michael Grunwald, TaeHyung (Simon) Kim et al. Nov 03, 2025 pp. 3749-3749 10.1182/blood-2025-3749

Abstract Background: Molecular markers associated with PV progression to myelofibrosis (MF) or acute myeloid leukemia (AML) remain limited. T...

Teclistamab induced rapid and deep hematologic response in relapsed/refractory light chain amyloidosis: A multicenter retrospective study

Kaini Shen, Liye Zhong, Peilong Lai et al. Nov 03, 2025 pp. 7492-7492 10.1182/blood-2025-7492

Abstract Objective: Daratumumab-based therapy has significantly improved the prognosis of patients with light chain (AL) amyloidosis. Howeve...

Cytotoxic, natural killer-like ex-tissue resident memory T-cells circulate in human chronic graft-versus-host disease at diagnosis

Patrick Mellors, Olga Shestova, Linda Perry et al. Nov 03, 2025 pp. 821-821 10.1182/blood-2025-821

Abstract Emerging evidence implicates tissue resident memory T-cells (TRM) in chronic graft-versus host disease (cGVHD) immunopathology. Whi...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page